Nextwave Pharms Drug Patent Portfolio
Nextwave Pharms owns 1 orange book drug protected by 10 US patents Given below is the list of Nextwave Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10857143 | Methylphenidate extended release chewable tablet | 14 Aug, 2033 | Active |
| US11103494 | Methylphenidate extended release chewable tablet | 14 Aug, 2033 | Active |
| US11103495 | Methylphenidate extended release chewable tablet | 14 Aug, 2033 | Active |
| US11633389 | Methylphenidate extended release chewable tablet | 14 Aug, 2033 | Active |
| US8999386 | Methylphenidate extended release chewable tablet | 14 Aug, 2033 | Active |
| US9295642 | Methylphenidate extended release chewable tablet | 14 Aug, 2033 | Active |
| US9545399 | Methylphenidate extended release chewable tablet | 14 Aug, 2033 | Active |
| US9844544 | Methylphenidate extended release chewable tablet | 14 Aug, 2033 | Active |
| US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product | 15 Feb, 2031 | Active |
| US8202537 | Modified release formulations containing drug-ion exchange resin complexes | 15 Mar, 2027 | Active |
Latest Legal Activities on Nextwave Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Nextwave Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jun, 2024 | US9545399 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 May, 2024 | US10857143 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2024 | US8287903 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Dec, 2023 | US8202537 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Sep, 2023 | US9295642 |
|
Email Notification
Critical
| 27 Apr, 2023 | US11633389 |
| Mail Miscellaneous Communication to Applicant | 27 Apr, 2023 | US11633389 |
|
Electronic Review
Critical
| 27 Apr, 2023 | US11633389 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 25 Apr, 2023 | US11633389 |
|
Recordation of Patent Grant Mailed
Critical
| 25 Apr, 2023 | US11633389 |
| Miscellaneous Communication to Applicant - No Action Count | 25 Apr, 2023 | US11633389 |
| Recordation of Patent eGrant | 25 Apr, 2023 | US11633389 |
|
Email Notification
Critical
| 06 Apr, 2023 | US11633389 |
|
Issue Notification Mailed
Critical
| 05 Apr, 2023 | US11633389 |
| Dispatch to FDC | 14 Mar, 2023 | US11633389 |
Nextwave Pharms's Family Patents
Nextwave Pharms drugs have patent protection in a total of 14 countries. It has a significant patent presence in the US with 62.4% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Nextwave Pharms Drug List
Given below is the complete list of Nextwave Pharms's drugs and the patents protecting them.
1. Quillichew Er
Quillichew Er is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10857143 | Methylphenidate extended release chewable tablet |
14 Aug, 2033
(8 years from now)
| Active |
| US11103494 | Methylphenidate extended release chewable tablet |
14 Aug, 2033
(8 years from now)
| Active |
| US11103495 | Methylphenidate extended release chewable tablet |
14 Aug, 2033
(8 years from now)
| Active |
| US11633389 | Methylphenidate extended release chewable tablet |
14 Aug, 2033
(8 years from now)
| Active |
| US8999386 | Methylphenidate extended release chewable tablet |
14 Aug, 2033
(8 years from now)
| Active |
| US9295642 | Methylphenidate extended release chewable tablet |
14 Aug, 2033
(8 years from now)
| Active |
| US9545399 | Methylphenidate extended release chewable tablet |
14 Aug, 2033
(8 years from now)
| Active |
| US9844544 | Methylphenidate extended release chewable tablet |
14 Aug, 2033
(8 years from now)
| Active |
| US8287903 | Orally effective methylphenidate extended release powder and aqueous suspension product |
15 Feb, 2031
(5 years from now)
| Active |
| US8202537 | Modified release formulations containing drug-ion exchange resin complexes |
15 Mar, 2027
(1 year, 8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Quillichew Er's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List